Ramatroban

Ramatroban
Clinical data
Trade names	Baynas
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral (tablets)
ATC code	None;
Legal status
Legal status	Rx-only (JP);
Identifiers
	IUPAC name 3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid;
CAS Number	116649-85-5;
PubChem CID	123879;
IUPHAR/BPS	1910;
ChemSpider	110413;
UNII	P1ALI72U6C;
KEGG	D01128;
ChEMBL	ChEMBL361812;
CompTox Dashboard (EPA)	DTXSID1046685 ;
ECHA InfoCard	100.159.668
Chemical and physical data
Formula	C21H21FN2O4S
Molar mass	416.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O;
	InChI InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1; Key:LDXDSHIEDAPSSA-OAHLLOKOSA-N;

Ramatroban (INN) (also known as Bay-u3405)[1] is a thromboxane receptor antagonist.[2]

It is also a DP₂ receptor antagonist.[3]

It is indicated for the treatment of coronary artery disease.[4] It has also been used for the treatment of asthma.[5]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the trade name Baynas.

References

"Ramatroban (compound)". PubChem. National Center for Biotechnology Information. Retrieved 22 June 2019.
Sugimoto H, Shichijo M, Iino T, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". J. Pharmacol. Exp. Ther. 305 (1): 347–52. doi:10.1124/jpet.102.046748. PMID 12649388.
Royer JF, Schratl P, Carrillo JJ, et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". Eur. J. Clin. Invest. 38 (9): 663–71. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743.
Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease" (PDF). Stroke. 21 (12 Suppl): IV149–51. PMID 2260140.
Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952.

External links

(in Japanese) Baynas Tablets Prescribing Information

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[PubChem-1] "Ramatroban (compound)". PubChem. National Center for Biotechnology Information. Retrieved 22 June 2019.

[pmid12649388-2] Sugimoto H, Shichijo M, Iino T, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". J. Pharmacol. Exp. Ther. 305 (1): 347–52. doi:10.1124/jpet.102.046748. PMID 12649388.

[pmid18837743-3] Royer JF, Schratl P, Carrillo JJ, et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". Eur. J. Clin. Invest. 38 (9): 663–71. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743.

[pmid2260140-4] Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease" (PDF). Stroke. 21 (12 Suppl): IV149–51. PMID 2260140.

[pmid8950952-5] Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952.